* Q4 LOSS PER SHARE $0.60

* ‍EXPECTS TO INITIATE STUDY MID-YEAR 2018 TO SUPPORT AN NDA FOR ZYN002 IN FXS​

* ZYNERBA PHARMACEUTICALS - BELIEVES ‍CASH,CASH EQUIVALENT POSITION AS OF DEC 31, 2017 IS SUFFICIENT TO FUND OPERATIONS, CAPITAL REQUIREMENTS WELL INTO 2019​

* ZYNERBA - BELIEVES CASH, CASH EQUIVALENT POSITION OF $62.5 MILLION AS OF DEC 31, 2017 SUFFICIENT TO FUND OPERATIONS, CAPITAL REQUIREMENTS WELL INTO 2019 Source text for Eikon: Further company coverage: